<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Equine serum heptavalent botulism antitoxin (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Equine serum heptavalent botulism antitoxin (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Equine serum heptavalent botulism antitoxin (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="88988" href="/d/html/88988.html" rel="external">see "Equine serum heptavalent botulism antitoxin (United States: Availability limited to Strategic National Stockpile distribution): Drug information"</a> and <a class="drug drug_patient" data-topicid="112801" href="/d/html/112801.html" rel="external">see "Equine serum heptavalent botulism antitoxin (United States: Availability limited to Strategic National Stockpile distribution): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F25341098"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antitoxin</span></li></ul></div>
<div class="block don drugH1Div" id="F53462683"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The total volume contained in one vial (regardless of vial size) will differ by lot number (~10 to 26 mL per vial). In order to calculate partial vial doses (eg, neonatal dosing), withdraw the entire contents of the vial to determine the total volume in the vial. Monitor patients closely for hypersensitivity reactions; patients with asthma, hay fever, history of hypersensitivity to horses, or previous exposure to equine-derived products are at a greater risk.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3dde2aa8-e5be-4a00-9fa7-c28f67e3cd42">Botulism, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Botulism, treatment:</b> Neonates: IV: 10% of the adult dose (adult dose is one vial), regardless of body weight. A repeat dose may be administered when the suspicion of botulism is high and the progression of paralysis continues after the initial dose should have taken effect (&gt;24 hours after dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33956777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33956777'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F16608427"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The total volume contained in one vial (regardless of vial size) will differ by lot number (~10 to 26 mL per vial). In order to calculate partial vial doses (eg, pediatric dosing), withdraw the entire contents of the vial to determine the total volume in the vial. Monitor patients closely for hypersensitivity reactions; patients with asthma, hay fever, history of hypersensitivity to horses, or previous exposure to equine-derived products are at a greater risk.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3dde2aa8-e5be-4a00-9fa7-c28f67e3cd42">Botulism, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Botulism, treatment: Note:</b> A repeat dose may be administered when the suspicion of botulism is high and the progression of paralysis continues after the initial dose should have taken effect (ie, &gt;24 hours after initial dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33956777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33956777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;1 year: IV: 10% of the adult dose (one vial), regardless of body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥1 year and Adolescents &lt;17 years: IV: 20% to 100% of the adult dose (adult dose is one vial) dependent upon patient weight; minimum dose: 20% of one vial; maximum dose: One vial.</p>
<p style="text-indent:-2em;margin-left:6em;">The percentage of the adult dose to be administered is based on patient weight according to the following Salisbury Rule equations:</p>
<p style="text-indent:-2em;margin-left:8em;">≤30 kg: Percentage (%) of Adult Dose to be Administered = Weight (kg) × 2</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;30 kg: Percentage (%) of Adult Dose to be Administered = Weight (kg) + 30</p>
<p style="text-indent:-2em;margin-left:6em;">The following doses are recommended using the above equations:</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Botulism Antitoxin Dosing Guide Based on Salisbury Rule: Children ≥1 Year of Age to &lt;17 Years of Age</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Body weight (kg)</p></th>
<th align="center">
<p style="text-indent:0em;">Percent of Adult Dose</p>
<p style="text-indent:0em;">
<b>(% of one vial)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to 14</p></td>
<td align="center">
<p style="text-indent:0em;">20%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 19</p></td>
<td align="center">
<p style="text-indent:0em;">30%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20 to 24</p></td>
<td align="center">
<p style="text-indent:0em;">40%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">25 to 29</p></td>
<td align="center">
<p style="text-indent:0em;">50%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to 34</p></td>
<td align="center">
<p style="text-indent:0em;">60%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">35 to 39</p></td>
<td align="center">
<p style="text-indent:0em;">65%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">40 to 44</p></td>
<td align="center">
<p style="text-indent:0em;">70%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">45 to 49</p></td>
<td align="center">
<p style="text-indent:0em;">75%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50 to 54</p></td>
<td align="center">
<p style="text-indent:0em;">80%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥55</p></td>
<td align="center">
<p style="text-indent:0em;">100%</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years: One vial.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51083166"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51083167"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F16608428"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="88988" href="/d/html/88988.html" rel="external">see "Equine serum heptavalent botulism antitoxin (United States: Availability limited to Strategic National Stockpile distribution): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61454e4a-5b3b-445f-ac19-932513908e98">Botulism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Botulism:</b> Treatment: <b>IV:</b> One vial; administer as soon as possible in the course of illness. A repeat dose may be administered when the suspicion of botulism is high and the progression of paralysis continues after the initial dose should have taken effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33956777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33956777'])">Ref</a></span>). <b>Note:</b> The total volume contained in one vial (regardless of vial size) will differ by lot number (~10 to 26 mL per vial).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990181"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987547"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F16608378"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (9%), chills (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (5%), urticaria (5%), skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≤5%), sore throat (&lt;4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Agitation, anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, asystole, bradycardia, bronchospasm, chest discomfort, erythema, hyperhidrosis, hypersensitivity reaction, hypotension, increased blood pressure, infusion related reaction, jitteriness, leukocytosis, serum sickness, tachycardia, urinary retention, vomiting</p></div>
<div class="block coi drugH1Div" id="F16608359"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling.</p></div>
<div class="block war drugH1Div" id="F16608362"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed allergic reaction: Delayed allergic reaction or serum sickness (eg, arthralgia, fever, lymphadenopathy, myalgia, urticarial or maculopapular rash) may occur 10 to 21 days after administration. Monitor all patients for delayed allergic reactions and administer appropriate medical care as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, may occur. The risk is greatest in patients with a history of hypersensitivity to horses or equine blood products, asthma, or hay fever; initiate treatment at the lowest achievable infusion rate (&lt;0.01 mL/minute) is recommended. Monitor all patients for acute allergic reactions during and following the infusion; discontinue antitoxin administration in patients who develop a hypersensitivity reaction. Immediate treatment (including epinephrine 1 mg/mL) should be available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Infusion reactions (eg, arthralgia, chills, fatigue, fever, headache, myalgia, nausea, vasovagal reactions, vomiting) may occur; monitor all patients for infusion reactions during and following the infusion. In patients who develop an infusion reaction, decrease the infusion rate and treat symptomatically; if symptoms worsen, discontinue the infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Maltose: May contain maltose which may falsely elevate glucose readings</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vial contents: Each vial contains a minimum antitoxin potency. The total volume contained in one vial (regardless of vial size) will differ by lot number (10 to 26 mL per vial); therefore, withdrawal of the entire vial contents will be required to calculate the dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Botulism: Antitoxin is most effective if administered as early as possible (ideally within 12 to 48 hours) after the onset of neurologic symptoms (Fagan 2011a). Antitoxin does not reverse existing paralysis, but it arrests its progression and may lead to faster resolution of the disease process (Yu 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Disease transmission: Product of equine (horse) plasma; may potentially contain infectious agents (eg, viruses) which could transmit disease. Infections thought to be transmitted by this product should be reported to the manufacturer at 1-800-768-2304 and the state health department supplying the antitoxin.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878789"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">The safety and efficacy information in pediatric patients is derived from animal model studies. Dosing in pediatric patients is based on the Salisbury Rule. Limited pediatric data safety data available; a CDC expanded access clinical study including 15 pediatric subjects (age range:  10 days to 17 years) reported adverse reactions in two patients; one subject experienced tachycardia, bradycardia, and asystole during infusion; pyrexia was reported in the other patient.</p></div>
<div class="block foc drugH1Div" id="F16610641"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Injection, solution [preservative free]: Each vial contains no less than serotype A antitoxin 4500 units, serotype B antitoxin 3300 units, serotype C antitoxin 3000 units, serotype D antitoxin 600 units, serotype E antitoxin 5100 units, serotype F antitoxin 3000 units, and serotype G antitoxin 600 units (20 mL, 50 mL)</p></div>
<div class="block geq drugH1Div" id="F16608351"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block accres drugH1Div" id="F16608350"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Heptavalent botulism antitoxin is not available for general public use. All supplies are currently owned by the federal government for inclusion in the Strategic National Stockpile and are distributed by the Centers for Disease Control and Prevention (CDC). Clinicians who suspect botulism in a patient are instructed to call their state health department’s emergency 24-hour telephone number; the state health department will contact the CDC to request release of botulism antitoxin, if indicated. State health departments can contact the CDC at their 24-hour telephone number at (770) 488-7100. Additional information from the CDC is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Flaboratory%2Fdrugservice%2Fformulary.html&amp;token=8fUMx%2BfB4trlY8x%2FMo8Y9Ddj5kItZ1H7qlW%2Fe3GJptY28xGubTU0DXWzUi5nl8%2BCwNhzfAcY95p7Mq5fGdd6Fg%3D%3D&amp;TOPIC_ID=98478" target="_blank">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p></div>
<div class="block admp drugH1Div" id="F52614533"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Should be diluted to a 1:10 dilution in NS prior to administration. Infuse through a 15-micron, sterile, nonpyrogenic, low protein-binding, in-line filter. A slower infusion rate should be used during the first 30 minutes of treatment; if tolerated, may increase rate every 30 minutes up to the maximum infusion rate for the remainder of the infusion. For patients at risk for hypersensitivity reaction, begin administration at the lowest achievable rate (&lt;0.01 mL/minute) and monitor. Monitor vital signs throughout the infusion. Initiate and increase the infusion rate as follows:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and Infants &lt;1 year: Initial: 0.01 mL/kg/minute; may increase the rate by 0.01 mL/kg/minute every 30 minutes to a maximum infusion rate of 0.03 mL/kg/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥1 year and Adolescents &lt;17 years: Initial: 0.01 mL/kg/minute (maximum initial rate: 0.5 mL/minute); may increase the rate by 0.01 mL/kg/minute every 30 minutes to a maximum infusion rate of 0.03 mL/kg/minute not to exceed 2 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years: Initial: 0.5 mL/minute; may double the infusion rate, if tolerated, every 30 minutes to a maximum infusion rate of 2 mL/minute.</p></div>
<div class="block adm drugH1Div" id="F16608478"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Use an IV line with constant infusion pump. Use a 15-micron, sterile, nonpyrogenic, low protein-binding, in-line filter. A slower infusion rate should be used during the first 30 minutes of treatment; if tolerated, may increase rate every 30 minutes up to the maximum infusion rate for the remainder of the infusion. Monitor vital signs throughout the infusion. Initiate and increase the infusion rate as follows:</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 0.5 mL/minutes; may double the infusion rate every 30 minutes to a maximum infusion rate of 2 mL/minute</p></div>
<div class="block sts drugH1Div" id="F16608384"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials frozen at ≤−15°C (≤5°F) until use; once thawed, may be stored at 2°C to 8°C (36°F to 48°F) for up to 36 months or until 48 months from date of manufacturer (whichever comes first).</p></div>
<div class="block usep drugH1Div" id="F53571069"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of symptomatic botulism following documented or suspected exposure to any of the seven serotypes of botulinum neurotoxin serotypes (serotypes A, B, C, D, E, F, or G) (FDA approved in pediatric patients [age not specified] and adults)</p></div>
<div class="block cyt drugH1Div" id="F17917883"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F17917881"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F16608356"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on limited information with the use of the previous equine products (BAT-AB; BAT-E), there is no indication that treatment of pregnant patients with botulism should differ from standard therapy (Arnon 2001).</p>
<p style="text-indent:0em;margin-top:2em;">Signs and symptoms of foodborne botulism may present differently in pregnant or postpartum patients. Weakness or fatigue and dry mouth may be more common than in nonpregnant patients. Pregnant patients may also be at an increased risk for respiratory failure (CDC [Rao 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant patients if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Pregnant patients with suspected foodborne botulism should be treated with botulism antitoxin in the same manner as non-pregnant patients (CDC [Rao 2021]).</p></div>
<div class="block mopp drugH1Div" id="F53571068"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor vital signs and for the presence of infusion-related reactions and acute hypersensitivity reactions during and immediately following infusion; monitor for delayed allergic reactions for 10 to 21 days after administration. </p></div>
<div class="block pha drugH1Div" id="F16608388"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Contains toxin-specific F(ab’)<sub>2</sub> and F(ab’)<sub>2</sub>-related antibody fragments which bind and neutralize free botulinum neurotoxin A, B, C, D, E, F, and G. As a result, the neurotoxins are prevented from interacting with the cholinergic nerve ending and internalizing into target cells, thereby minimizing nerve damage and severity of the disease. Clinicians should note that botulism antitoxin does not reverse preexisting toxic manifestations.</p></div>
<div class="block phk drugH1Div" id="F16608392"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype A: 3.6 L</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype B: 9.6 L</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype C: 6.1 L</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype D: 1.5 L</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype E: 14.2 L</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype F: 3.4 L</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype G: 2.4 L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype A: 8.6 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype B: 34.2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype C: 29.6 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype D: 7.5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype E: 7.8 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype F: 14.1 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Antitoxin serotype G: 11.7 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58209746"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Botulismus-antitoxin behring</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Purified adsorbed trianatoxin | Trianatoxin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11209178">
<a name="11209178"></a>Arnon SS, Schechter R, Inglesby TV, et al ; Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management [published correction appears in <i>JAMA</i>. 2001;285(16):2081]. <i>JAMA</i>. 2001;285(8):1059-1070.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/11209178/pubmed" id="11209178" target="_blank">11209178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  BAT (botulism antitoxin heptavalent [A, B, C, D, E, F, G] - [equine] solution for injection) [product monograph]. Winnipeg, Manitoba, Canada: Emergent BioSolutions Canada Inc; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20300057">
<a name="20300057"></a>Centers for Disease Control and Prevention (CDC), "Investigational Heptavalent Botulinum Antitoxin (HBAT) to Replace Licensed Botulinum Antitoxin AB and Investigational Botulinum Antitoxin E," <i>MMWR Morb Mortal Wkly Rep</i>, 2010, 59(10):299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/20300057/pubmed" id="20300057" target="_blank">20300057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29410923">
<a name="29410923"></a>Diaz A, Sharma S. A Case of a 34-year-old female with acute hypoxemic respiratory failure and proximal muscle weakness. <i>Case Rep Crit Care</i>. 2017;2017:7941715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/29410923/pubmed" id="29410923" target="_blank">29410923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292663">
<a name="21292663"></a>Fagan RP, McLaughlin JB, Castrodale LJ, et al. Endemic foodborne botulism among Alaska Native persons--Alaska, 1947-2007. <i>Clin Infect Dis</i>. 2011a;52(5):585-592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/21292663/pubmed" id="21292663" target="_blank">21292663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21896700">
<a name="21896700"></a>Fagan RP, Neil KP, Sasich R, et al, "Initial Recovery and Rebound of Type F Intestinal Colonization Botulism After Administration of Investigational Heptavalent Botulinum Antitoxin," <i>Clin Infect Dis</i>, 2011b, 53(9):e125-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/21896700/pubmed" id="21896700" target="_blank">21896700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29449118">
<a name="29449118"></a>Garcia E, Zaid AH, Calello DP, et al. Shot by a gun … missed by a provider. <i>J Emerg Med</i>. 2018;54(4):e61-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/29449118/pubmed" id="29449118" target="_blank">29449118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23362041">
<a name="23362041"></a>Hill, SE, Iqbal, R., Cadiz, CL, et al, "Foodborne Botulism Treated With Heptavalent Botulism Antitoxin," <i>Ann Pharmacother</i>, 2013, 47(2):e12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/23362041/pubmed" id="23362041" target="_blank">23362041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29293927">
<a name="29293927"></a>O'Horo JC, Harper EP, El Rafei A, et al. Efficacy of antitoxin therapy in treating patients with foodborne botulism: a systematic review and meta-analysis of cases, 1923-2016. <i>Clin Infect Dis</i>. 2017;66(suppl 1):S43-S56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/29293927/pubmed" id="29293927" target="_blank">29293927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956777">
<a name="33956777"></a>Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical guidelines for diagnosis and treatment of botulism, 2021. <i>MMWR Recomm Rep</i>. 2021;70(2):1-30. doi:10.15585/mmwr.rr7002a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/33956777/pubmed" id="33956777" target="_blank">33956777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29293931">
<a name="29293931"></a>Schussler E, Sobel J, Hsu J, et al. Workgroup report by the Joint Task Force involving American Academy of Allergy, Asthma &amp; Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup – allergic reactions to botulinum antitoxin: a systematic review. <i>Clin Infect Dis</i>. 2017;66(suppl 1):S65-S72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/29293931/pubmed" id="29293931" target="_blank">29293931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29293928">
<a name="29293928"></a>Yu PA, Lin NH, Mahon BE, et al. Safety and improved clinical outcomes in patients treated with new equine-derived heptavalent botulinum antitoxin. <i>Clin Infect Dis</i>. 2017;66(suppl 1):S57-S64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/29293928/pubmed" id="29293928" target="_blank">29293928</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 98478 Version 62.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
